Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tafamidis
Pharma
Pfizer fends off generic Vyndamax entry until 2031
Pfizer now anticipates its Vyndamax sales to remain “relatively stable” from 2028 through mid-2031, it said.
Zoey Becker
Apr 28, 2026 4:30pm
Pfizer inks settlements with 2 generic Vyndamax contenders
Apr 27, 2026 11:23am
BridgeBio shares slide on Pfizer's ATTR patent withdrawal
Feb 6, 2026 10:50am
Is Pfizer's recent ATTR sales decline in the US a warning sign?
Dec 2, 2025 8:20am
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Aug 29, 2025 10:40am
Alnylam's market cap jumps past $50B
Aug 1, 2025 7:39am
